Concepts of Combating Chemoresistance in Cancer Therapeutics.

Format:

Book

Author/Creator:

Goel, Honey.

Contributor:

Srivastava, Saurabh.

Singla, Richu.

Talegaonkar, Sushama.

Language:

English

Physical Description:

1 online resource (776 pages)

Edition:

1st ed.

Place of Publication:

Chantilly : Elsevier Science & Technology, 2025.

Summary:

Concepts of Combating Chemoresistance in Cancer Therapeutics explores the fundamental issues and challenges related to cancer chemotherapeutics, emphasizing mechanisms and factors that lead to chemoresistance in various cancer types.

Contents:

Front Cover

Concepts of Combating Chemoresistance in Cancer Therapeutics

Copyright Page

Contents

List of contributors

About the authors

Preface

1 Conceptual paradigms of cancer chemoresistance

1.1 Introduction

1.2 The evolutionary and ecological dynamics of chemoresistance

1.2.1 Traditional versus adaptive therapies

1.2.2 Clinical prospects of evolution-informed treatment strategies

1.3 Innate (intrinsic) and acquired resistance

1.3.1 Innate (or Intrinsic) resistance

1.3.2 Acquired resistance

1.4 Critical factors involved in chemoresistance

1.4.1 Tumor heterogeneity

1.4.2 Tumor microenvironment and immune system

1.4.3 Tumor burden

1.4.4 Undruggable genome

1.4.5 Senescence escape

1.4.6 Physical barriers

1.5 Mechanistic framework for understanding the drug resistance

1.5.1 Drug inactivation

1.5.2 Alteration in drug targets

1.5.3 Drug efflux

1.5.4 DNA damage repair

1.5.5 Cell death inhibition

1.5.6 Epithelial-mesenchymal transition and metastasis

1.5.7 Epigenetic modifications

1.6 Strategic therapeutic management for combating drug resistance

1.6.1 Early diagnosis of cancer

1.6.2 Enhancing the drug effectiveness

1.6.3 Early diagnosis of chemoresistance

1.6.4 Combination therapy

1.6.5 Use of inhibitors

1.6.6 Use of natural products

1.7 Cancer stem cells

1.7.1 Cancer stem cells for cancer treatment

1.7.1.1 Pluripotent stem cells (PSCs)

1.7.1.2 Adult stem cells

1.7.1.3 Cancer stem cells

1.7.2 Approach for targeting cancer stem cells

1.7.3 Mechanism of cancer stem cells

1.7.3.1 ATP- binding cassette transporters and cancer stem cells

1.7.3.2 Aldehyde dehydrogenase-related chemoresistance

1.7.3.3 Pro-survival B-cell lymphoma-2 protein in CSCs.

1.7.3.4 Role of cancer stem cell-related signaling pathways in chemoresistance

1.7.3.5 Altered DNA damage response in cancer stem cells

1.8 Challenges and future directions

References

2 Mechanisms of multidrug resistance in cancer

2.1 Introduction

2.2 Acquired drug resistance

2.2.1 Enhanced drug efflux

2.2.1.1 ABC transporter superfamily

2.2.1.1.1 P-glycoprotein (P-gp/ABCB1)

2.2.1.1.2 Multidrug resistance-associated protein 1 (MRP1/ABCC1)

2.2.1.1.3 Breast cancer resistance protein (BCRP/ABCG2)

2.2.2 Reduced drug uptake

2.2.2.1 Alterations in membrane permeability

2.2.2.2 Downregulation of drug uptake transporters

2.2.2.3 Modifications to the tumor microenvironment

2.2.2.4 Strategies to overcome reduced drug uptake

2.3 Intrinsic drug resistance in glioma

2.3.1 Inhibition of cell death (apoptosis pathway blocking)

2.3.1.1 Overexpression of antiapoptotic proteins

2.3.1.1.1 B-cell lymphoma 2

2.3.1.1.2 B-cell lymphoma-extra large

2.3.1.1.3 Myeloid cell leukemia 1

2.3.1.2 Dysregulation of pro-apoptotic proteins

2.3.1.2.1 Bcl-2 homologous antagonist/killer and Bcl-2-associated X protein

2.3.1.2.2 BH3-only proteins (e.g., Bid, Bim, and PUMA)

2.3.1.2.3 Caspases

2.3.1.3 Alterations in p53 signaling

2.3.2 Alteration in drug metabolism

2.3.2.1 O6-methylguanine-DNA methyltransferase

2.3.2.2 Glutathione S-transferases

2.3.2.3 Cytochrome P450 enzymes

2.3.2.4 UDP-glucuronosyltransferases

2.3.3 Modification in chemotherapeutic drug targets

2.3.3.1 Epidermal growth factor receptor

2.3.3.2 Isocitrate dehydrogenase mutations

2.3.3.3 Thymidylate synthase overexpression

2.3.3.4 P-glycoprotein overexpression

2.3.3.5 Posttranslational modifications

2.3.4 Augmenting the DNA damage repair

2.3.4.1 DNA damage repair mechanisms in gliomas.

2.3.4.2 Homologous recombination repair

2.3.4.3 Nonhomologous end joining

2.3.4.4 Clinical implications and emerging therapeutic strategies

2.4 Emerging pathways in drug resistance

2.4.1 Senescence escape in gliomas

2.4.1.1 Alterations in senescence pathways

2.4.1.2 Autophagy and senescence escape

2.4.1.3 Epigenetic modifications

2.4.1.4 Signaling pathways and senescence escape

2.4.1.5 Clinical implications and emerging strategies

2.4.2 Gene amplification and gene polymorphism in gliomas

2.4.2.1 Gene amplification in gliomas

2.4.2.2 Gene polymorphism in gliomas

2.4.3 Epigenetic alterations causing drug resistance in gliomas

2.4.3.1 Histone modifications and drug resistance

2.4.3.2 DNA methylation and drug resistance

2.4.3.3 Noncoding RNAs and drug resistance

2.4.4 MicroRNA in cancer drug resistance: subtypes of miscellaneous pathways

2.4.4.1 MicroRNAs and core signaling pathways

2.4.4.2 miRNAs involved in multidrug resistance

2.4.4.3 miRNA-based therapeutic strategies

2.4.5 Role of epithelial-mesenchymal transition as a critical regulator in miscellaneous pathways

2.4.5.1 Epithelial-mesenchymal transition and drug resistance pathways

2.4.5.2 Signaling pathways regulated by epithelial-mesenchymal transition

2.4.5.3 Epithelial-mesenchymal transition and tumor microenvironment

2.4.6 Adenosine triphosphate and adenosine triphosphate-mediated drug resistance: intracellular and extracellular mechanisms

2.4.6.1 ATP and intracellular drug resistance

2.4.6.2 ATP and extracellular drug resistance

2.4.6.3 Mechanistic insights and future directions

2.5 Conclusion

3 Therapeutic monitoring and adaptive strategies for combating drug resistance in cancer

3.1 Introduction

3.2 Factors involved in drug resistance

3.2.1 Tumor microenvironment.

3.2.2 Drug inactivation

3.2.3 Autophagy and apoptotic pathway inhibition

3.2.4 Drug resistance due to epithelial cell trans-differentiation

3.3 Chemotherapeutic drug monitoring

3.4 Strategies to overcome drug resistance in cancer

3.4.1 Multidrug resistance modulators

3.4.2 Modified nanoparticles for targeted therapy

3.4.3 RNA interference therapy

3.4.4 Nanoparticles loaded with chemotherapeutic agents and siRNAs

3.5 Conclusion

4 Novel therapeutic interventions to overcome drug resistance in cancer: targeting key regulators of the apoptotic pathway

4.1 Introduction

4.2 Understanding drug resistance in cancer-definition and mechanisms

4.3 Impact of drug resistance on treatment outcomes in cancer

4.4 The apoptotic pathway: a key player in cancer therapy

4.5 Mechanisms of apoptosis dysregulation

4.6 Mechanisms of drug resistance in cancer cells: role of apoptotic pathway

4.6.1 Apoptosis evasion

4.6.2 Dysregulation of apoptotic signaling

4.7 Key drug regulators of the apoptotic pathway

4.7.1 B-cell lymphoma 2 family protein

4.7.2 Structural domains and members of B-cell lymphoma 2 family protein

4.7.3 Inhibitor of apoptosis proteins

4.7.4 Family members of inhibitors of apoptosis proteins

4.7.5 Molecular structural features of inhibitors of apoptosis proteins

4.7.6 p53 tumor suppressor protein

4.7.7 Function and the structure of p53 tumor suppressor protein

4.7.8 Therapeutic agents targeting B-cell lymphoma 2 family proteins

4.7.9 Antisense oligonucleotides

4.7.10 BH3-mimetics

4.7.11 Gossypol

4.7.12 Obatoclax

4.7.13 ABT-737

4.7.14 Navitoclax

4.7.15 Venetoclax

4.7.16 BCL-XL-selective BH3-mimetics

4.7.17 MCL-1 antagonists

4.7.18 Targeting BH4

4.8 Therapeutic agents targeting inhibitors of apoptosis proteins

4.8.1 SMAC-mimetics.

4.8.2 Birinapant

4.8.3 LCL-161

4.8.4 DEBIO 1143

4.8.5 Other prominent SMAC-mimetics

4.8.6 Selective XIAP inhibitors

4.8.7 Restoring tumor suppressor gene function

4.8.8 Epigenetic drugs

4.9 Natural agents and derivatives

4.10 Nanomedicines

4.11 Challenges to overcome drug resistance in cancer

4.12 Future aspects to overcome drug resistance

4.13 Drug alteration tactics

4.14 Conclusion

5 Nutraceuticals for combating cancer chemoresistance

5.1 Introduction

5.1.1 Dietary fiber

5.1.2 Microecologics: prebiotics, probiotics, synbiotics, postbiotics, and paraprobiotics

5.2 The expansion of nutraceutical phytochemicals as chemosensitizers

5.2.1 Polyphenolic compounds

5.2.2 Curcumin

5.2.3 Resveratrol

5.2.4 Epigallocatechin gallate

5.2.5 Quercetin

5.2.6 Betulinic Acid (BA)

5.2.7 Plumbagin

5.2.8 Sinomenine

5.2.9 Oxymatrine

5.2.10 Nerolidol

5.2.11 Gambogic acid

5.2.12 Soy isoflavones

5.2.13 Vitamins

5.2.14 Lipids and polyunsaturated fatty acids

5.2.15 Carotenoids

5.3 A roller-coaster interplay between nutraceuticals and chemoresistance

5.3.1 Changing the drug metabolism

5.3.2 Augmenting the DNA repair

5.3.3 Inactivation of the anticancer drugs

5.3.4 Multidrug resistance via (adenosine triphosphate synthase (ATP) binding cassette transporters

5.3.5 Reducing the absorption of the drugs

5.3.6 Inhibition of the cell death

5.4 Challenges and limitations

5.4.1 Bioavailability and formulation issues

5.4.2 Lipid-based nanocarriers

5.4.3 Polysaccharide-based nanocarriers

5.5 Interactions with chemotherapeutic agents

5.5.1 Targeting cancer stem cells

5.5.2 Chemoresistant characteristics of cancer stem cells

5.6 Clinical investigations and patent data on applications of nutraceuticals in cancer.

5.7 Regulatory perspective on nutraceuticals.

Notes:

Description based on publisher supplied metadata and other sources.

Other Format:

Print version: Goel, Honey Concepts of Combating Chemoresistance in Cancer Therapeutics

ISBN:

9780443333446

OCLC:

1548593820